




Comparison of Mobi-C to Anterior Cervical Discectomy and Fusion at Two Contiguous Levels



Mobi-C[®]

Cervical Disc

IDE Clinical Trial Overview

Mobi-C demonstrated superiority in overall trial success compared to ACDF at two-levels





“
ANATOMICAL DESIGN
THAT FITS THE
NATURAL VERTEBRAL
ANATOMY

Table of Contents

KEY TRIAL RESULTS	4
OVERALL TRIAL SUCCESS: THE COMPOSITE ENDPOINT	5
COMPOSITE ENDPOINT COMPONENTS	6
Neck Disability Index	6
Subsequent Surgeries at the Treated Levels	7
Neurologic Status	7
Adverse Events Determined to Be Major Complications	8
SECONDARY ENDPOINTS	9
Adjacent Segment Degeneration	9
Adjacent Segment Surgeries	9
Radiographic Fusion Results for the ACDF Subjects	10
Range of Motion (ROM) Results for the Mobi-C Subjects	10
Subject Satisfaction	10
CLINICAL ENDPOINTS	11
Visual Analogue Scale	11
Return to Work	11
Heterotopic Ossification	11
CONCLUSION	12
APPENDIX	13
Trial Design	13
Subject Accounting	13
Subject Demographics	13
Surgery Data	13
Inclusion Criteria	14
Exclusion Criteria	15-17
Commonly Reported Adverse Events	17
Subsequent Surgical Interventions at the Index Level - Procedure Details	18
Indications	19

KEY TRIAL RESULTS




FEATURING
PATENTED MOBILE
BEARING
TECHNOLOGY

Mobi-C demonstrated:

Superiority in overall trial success

compared to ACDF at 84 months. The difference between Mobi-C's success rate of 60.8% and ACDF's rate of 34.6% is statistically superior.



*Fisher's Exact test used to compare treatments.

NOTE: Overall success based on IDE-defined primary endpoint.

At 84 months

- Nominally fewer subsequent surgeries at the index levels compared to ACDF.
- Lower average rates of adverse events determined to be major complications compared to ACDF.
- Lower average rates of adjacent level degeneration compared to ACDF.
- A higher NDI success rate compared to ACDF.
- A mean ROM in F/E of 9.3° at the superior index level and 7.4° at the inferior index level.

A mean return to work time 20.9 days sooner than ACDF.

Mobi-C is a safe and effective surgical option at two contiguous levels in the cervical spine from C3-C7 in indicated subjects.

NOTE: Please refer to ZimVie.com for complete study results.

OVERALL TRIAL SUCCESS: THE COMPOSITE ENDPOINT

Success Criteria


The Mobi-C IDE trial was a multi-center, prospective, and randomized controlled trial. Mobi-C, the investigational treatment, was compared to the control, anterior cervical discectomy and fusion (ACDF). The two-level trial included 330 randomized subjects, 225 Mobi-C and 105 ACDF subjects (a 2 to 1 ratio, respectively).

Trial success was based on a composite endpoint. A subject was considered a success at 84 months if all of the following criteria were met:


- Sufficient NDI improvement (≥ 15 points in subjects with baseline ≥ 30 points, or $\geq 50\%$ improvement in subjects with baseline < 30 points)
- No subsequent surgery at the treated level
- No major complications defined as:
 - No radiographic failure
 - No neurologic deterioration
 - No adverse event determined to be a major complication

Results

Mobi-C established superiority to ACDF at two contiguous levels.



Two-level Overall Trial Success Over Time



COMPOSITE ENDPOINT COMPONENTS

NECK DISABILITY INDEX (NDI)

Success Criteria

NDI is measured using a subject answered questionnaire, which assesses the effect of pain on daily life.


Each of the 10 assessed criteria[§] receives a score from 0 to 5; the highest score (50 points) represents the most disabled. The final score can be converted to a percentage.

[§]NOTE: NDI assessed criteria includes: pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation.

If baseline NDI:	NDI score improvement at 60 months must be:
≥ 30 points out of 50 points	≥ 15 points out of 50 points
< 30 points out of 50 points	≥ 50% improvement


Results

Two-level NDI Success



† Fisher's Exact test used to compare treatments.

Two-level Mean NDI Over Time: A Clinical Endpoint



COMPOSITE ENDPOINT COMPONENTS *(continued)*

SUBSEQUENT SURGERIES AT THE TREATED LEVELS

Success Criteria

The subject was considered a success in terms of subsequent surgery if none of the following were necessary at the treated levels: removal, revision, reoperation, or supplemental fixation.


Results

Mobi-C had fewer subsequent surgeries on average compared to ACDF through 84 months.

As shown in the chart:

Mobi-C had fewer subsequent surgeries on average

compared to ACDF through 84 months.



NOTE: See page 18 for details on subsequent surgical interventions.

NEUROLOGIC STATUS

Success Criteria


Neurologic status was measured using motor, sensory-light touch, sensory-pin prick, and reflex assessments.

The surgery was considered a success if neurological status was maintained or improved.

Results

As expected, both treatment groups demonstrated similar percentages of subjects with stable or improved neurologic status at 84 months.

Two-level Neurologic Status: Maintained or Improved



COMPOSITE ENDPOINT COMPONENTS *(continued)*

ADVERSE EVENTS DETERMINED TO BE MAJOR COMPLICATIONS


Success Criteria

The Clinical Events Committee (CEC) independently determined if an adverse event (AE) was a major complication.

If so, the subject was considered a study failure.

Results

Two-level AEs Deemed to be a Major Complication



COMMONLY REPORTED ADVERSE EVENTS

NOTE: Adverse event data includes the Mobi-C non-randomized training cases.

Commonly Reported AEs Through Month 84	Mobi-C	ACDF
Neck pain	41.0%	61.0%
Arm pain	25.6%	30.5%
Neck and arm pain	5.1%	7.6%
Back pain	36.8%	32.4%
Shoulder pain	29.1%	42.9%
Headache	27.4%	27.6%
Neurological - upper extremity sensory	42.7%	53.3%
Neurological - neck	20.5%	21.0%
Dysphagia	17.1%	22.9%
Dysphonia	2.6%	1.9%
Surgical wound infection	3.4%	3.8%
Nonunion (ACDF only)	–	14.3%
Heterotopic ossification at index levels (Mobi-C only)	8.5%	–
Unanticipated adverse device effect	0.9%	3.8%

SECONDARY ENDPOINTS

ADJACENT SEGMENT DEGENERATION

Success Criteria

Adjacent segment degeneration was assessed at the spinal segment immediately above and below the treated levels.


An independent core lab assessed degeneration using the Kellgren-Lawrence five point grading scale.*

An adjacent segment was counted as having degenerated if the segment worsened by 1 grade or more.

*NOTE: The Kellgren-Lawrence scale looks at radiographs for evidence of disc degenerative changes, including the absence or presence of osteophytes, disc narrowing, and endplate sclerosis. The five grades are: none (0), minimal (1), definite (2), moderate (3), or severe (4).

Results

Clinically Relevant* Adjacent Segment Degeneration at Two-levels




*NOTE: Grades 0, I, or II were defined as not being clinically relevant, while grades III or IV were defined as clinically relevant.

ADJACENT SEGMENT SURGERIES

Results

Two-level Adjacent Segment Surgeries



SECONDARY ENDPOINTS

(continued)

RADIOGRAPHIC FUSION RESULTS FOR THE ACDF SUBJECTS


		Fusion Status
IDE Study	6M	42/94 (44.7%)
	12M	58/92 (63.0%)
	24M	77/96 (80.2%)
	36M	73/84 (86.9%)
	48M	74/86 (86.0%)
PAS Study	60M	70/81 (86.4%)
	84M	60/66 (90.9%)

†NOTE: Percent of randomized subjects with available data.

RANGE OF MOTION (ROM) RESULTS FOR THE MOBI-C SUBJECTS

Results

Randomized Mobi-C subjects demonstrated mean ROM at the inferior index level of 7.4° for flexion-extension and 4.9° for lateral bending. At the superior index level, Mobi-C subjects demonstrated mean ROM of 9.3° for flexion-extension and 4.8° for lateral bending.†



SUBJECT SATISFACTION

Success Measurement

Question	Possible Answers
1. How satisfied are you with the surgical treatment you received?	Very satisfied, somewhat satisfied, somewhat dissatisfied, or very dissatisfied
2. Would you recommend the same treatment to a friend with the same condition?	Definitely yes, probably yes, probably no, or definitely no

Results*

Mobi-C	ACDF
Very Satisfied at 84M	
86.0%	73.9%
Definitely Yes at 84M	
81.6%	69.6%

*NOTE: Randomized subjects with available data.

CLINICAL ENDPOINTS


VISUAL ANALOGUE SCALE (VAS)

Success Criteria


Subjects were asked to separately rate their neck and left and right arm pain. The VAS score is measured on a 100 mm line with 'No Pain' on the left and 'Worst Possible Pain' on the right. The subject marks a point on the line that best represents his or her pain.

The distance is then measured in millimeters from 'No Pain' on the left to the subject's mark to create the VAS score.

Results: Neck



Results: Arm



NOTE: The combined arm score was based on the most symptomatic arm at baseline carried forward.

RETURN TO WORK

Success Measurement

The number of days from surgery until the subject was able to return to work was counted.

Results

Return to Work	Randomized Mobi-C	Randomized ACDF
Mean time (days)	45.9	66.8

HETEROTOPIC OSSIFICATION

Success Criteria

Mobi-C radiographs were assessed for heterotopic ossification using a classification system adapted from McAfee and Mehren.* HO was assessed by two independent radiologists with a third radiologist adjudicating in instances of disagreement.

Results

HO at 84 Months (Randomized subjects with available data)		Superior Level	Inferior Level
		Not Clinically Relevant	Grade 0/I/II
Clinically Relevant	Grade III/IV	23.1%	30.1%

NOTE: Although use of NSAIDs was not part of the post-operative regimen, 25.8% of randomized Mobi-C subjects reported use of NSAIDs between discharge to week 6 and 23.1% between week 6 and month 3. Based on independent assessment of HO, there was a small negative correlation between post-operative NSAID use and HO at month 24 that approaches but does not reach significance.

*NOTE: Grades 0, I, or II were defined as not being clinically relevant, while grades III or IV were defined as clinically relevant.

CONCLUSION

Mobi-C demonstrated:

At 84 months

Nominally fewer subsequent surgeries at the index levels compared to ACDF.

Lower average rates of adverse events determined to be major complications compared to ACDF.

Lower average rates of adjacent level degeneration compared to ACDF.

A higher NDI success rate compared to ACDF.

A mean ROM in F/E of 9.3° at the superior index level and 7.4° at the inferior index level.

A mean return to work time 20.9 days sooner than ACDF.



THIS CLINICAL TRIAL ESTABLISHED THAT MOBI-C AT TWO CONTIGUOUS LEVELS IS STATISTICALLY SUPERIOR TO ACDF AT 84 MONTHS FOR OVERALL TRIAL SUCCESS.



Conclusion:

Mobi-C is a safe and effective

surgical option at two contiguous levels in the cervical spine from C3-C7 for indicated subjects.

NOTE: Please refer to ZimVie.com for complete study results.

APPENDIX

TRIAL DESIGN

The Mobi-C IDE trial was multi-center, prospective, and randomized controlled trial. The trial tested Mobi-C for non-inferiority to the current standard of care, ACDF.

The trial planned for the testing of superiority in the event that non-inferiority was established. The primary trial endpoint analysis was based upon 24 month results.

The IDE trial consisted of one-level and two-level treatment arms conducted simultaneously under the same FDA-approved protocol.

(This document focuses on the two-level treatment arm).

Investigational Treatment:

- Anterior discectomy followed by insertion of Mobi-C at two-levels

Control Treatment:

- Anterior discectomy followed by insertion of allograft bone at two-levels and an anterior cervical plate (*DePuy Spine Slim-Loc® or the Medtronic Atlantis® or Atlantis Vision®*)

Randomization Scheme:

- 2 to 1 ratio, Mobi-C to ACDF respectively

330 Randomized Subjects:

- 225 Mobi-C
- 105 ACDF

The trial allowed for 1 nonrandomized training case per site and resulted in 9 nonrandomized Mobi-C subjects in the two-level arm

24 Investigative Sites

Post-operative follow-up for the IDE trial:

- 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, and 48 months

Post-operative follow-up for the Post-Approval Studies:

- 60 months and 84 months

SUBJECT ACCOUNTING

Subject Accounting (Two-level)	Randomized Mobi-C	Randomized ACDF
Subjects Treated	225	105
Subjects with Data at 84 Months	173	63
Expected Number of Subjects at 84 Months	205	84
Follow-up Rate at 84 Months	84.4% of randomized Mobi-C and 75.0% ACDF subjects presented some data at 84 months.	

SUBJECT DEMOGRAPHICS

Demographics were similar for both treatment groups. A breakdown of the data for all randomized subjects is provided in the table below for comparison.

Demographics at Baseline (Two-level)	Randomized Mobi-C	Randomized ACDF	P-value
Male	50.2%	42.9%	0.2375*
Female	49.8%	57.1%	
Mean age (years)	45.3	46.2	0.3725**
Mean BMI (kg/M²)	27.6	28.1	0.3586**
Ethnicity			>0.9999*
- Hispanic or Latino	6.2%	6.7%	
- Not Hispanic or Latino	93.8%	93.3%	
Race			>0.9999*
- Caucasian	94.2%	94.3%	
- Black/African American	2.2%	3.8%	
- Asian	1.8%	0.0%	
- American Indian/Alaskan Native	1.3%	1.0%	
- Other	0.4%	1.0%	
Work status			>0.9999*
- Able to work	62.7%	61.0%	
Driving Status			0.4026*
- Able to drive	93.3%	97.1%	
Smoke more than one pack per day			>0.9999*
- Yes	0%	0%	
- No	100%	100%	

*Fisher's Exact test used to compare treatments.

** An unpaired test used to compare treatment groups.

SURGERY DATA

Surgery Data (Two-level)	Randomized Mobi-C	Randomized ACDF
Mean Est. Blood Loss (mls)	67.0	70.3
Mean Length of Hospital Stay (days)	2.2	2.4
Mean Operative Time (hrs)	2.1	1.8
Levels Treated (Two-level)		
C3-C5	0.4%	1.9%
C4-C6	26.7%	21.9%
C5-C7	72.9%	76.2%

INCLUSION CRITERIA

Enrollment in the two-level Mobi-C trial arm was limited to subjects who met the following inclusion criteria.

1. Age 18-69 years.
2. Diagnosis of radiculopathy or myeloradiculopathy of the cervical spine, with pain, paresthesias or paralysis in a specific nerve root distribution C3 through C7, including at least one of the following:
 - Neck and/or arm pain (at least 30 mm on the 100 mm visual analogue scale [VAS] scale).
 - Decreased muscle strength of at least one level on the clinical evaluation 0 to 5 scale.
 - Abnormal sensation including hyperesthesia or hypoesthesia; and/or
 - Abnormal reflexes.
3. Symptomatic at two contiguous levels from C3 to C7.
4. Radiographically determined pathology at two contiguous level(s) to be treated correlating to primary symptoms including at least one of the following:
 - Decreased disc height on radiography, computed tomography (CT), or magnetic resonance imaging (MRI) in comparison to a normal adjacent disc.
 - Degenerative spondylosis on CT or MRI.
 - Disc herniation on CT or MRI.
5. NDI Score of $\geq 15/50$ or $\geq 30\%$.
6. Unresponsive to nonoperative, conservative treatment (rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics) for:
 - Approximately six weeks from radiculopathy or myeloradiculopathy symptom onset; or
 - Have the presence of progressive symptoms or signs of nerve root/spinal cord compression despite continued nonoperative conservative treatment.
7. Appropriate for treatment using an anterior surgical approach, including having no prior surgery at the operative level and no prior cervical fusion procedure at any level.
8. Reported to be medically cleared for surgery.
9. Reported to be physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms and willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol.
10. Written informed consent provided by subject or subject's legally authorized representative.
11. Willingness to discontinue all use of non-steroidal anti-inflammatory drugs (NSAIDs) from one week before surgery until 3 months after surgery.

EXCLUSION CRITERIA

Subjects were **NOT** permitted to enroll in the Mobi-C study if they met any of the following exclusion criteria.

1. Reported to have an active systemic infection or infection at the operative site.
2. Reported to have a history of or anticipated treatment for active systemic infection, including HIV or Hepatitis C.
3. More than one immobile vertebral level between C1 to C7 from any cause including but not limited to congenital abnormalities and osteoarthritic "spontaneous" fusions.
4. Previous trauma to the C3 to C7 levels resulting in significant bony or disco-ligamentous cervical spine injury.
5. Reported to have had any prior spine surgery at the operative levels.
6. Reported to have had a prior cervical fusion procedure at any level.
7. Axial neck pain in the absence of other symptoms of radiculopathy or myeloradiculopathy justifying the need for surgical intervention.
8. Disc height less than 3 mm as measured from the center of the disc in a neutral position and disc height less than 20% of the anterior-posterior width of the inferior vertebral body.
9. Radiographic confirmation of severe facet joint disease or degeneration.
10. Reported to have an increased risk of osteoporosis/osteopenia. This was defined as a T-score less than (worse than) -1.5 on a previous or required Hologic Sahara or dual energy X-ray absorptiometry (DEXA) scan.

All subjects that met one or more of the following were to undergo a Hologic Sahara or DEXA scan as part of the study enrollment procedures:

- Females 50 years and older;
- Females who were post-menopausal or post-hysterectomy with oophorectomy;
- Subjects taking bisphosphonate medication for the treatment of osteoporosis; and/or
- Subjects with history of chronic use of high dose steroids. High dose steroid use is defined as part of Exclusion Criterion #22.

All females less than 50 years of age, and all males, who had not had a Hologic Sahara or DEXA scan within six months of surgery, were screened for osteoporosis using the Simple Calculated Osteoporosis Risk Estimation (SCORE) questionnaire.

Subjects whose screening suggests increased risk (SCORE greater than 6) were to undergo a Hologic Sahara or DEXA scan as part of the study enrollment procedures.

11. Reported to have Paget's disease, osteomalacia or any other metabolic bone disease other than osteoporosis, (which is addressed on the previous page).
12. Reported active malignancy that included a history of any invasive malignancy (except non-melanoma skin cancer), unless the subject had been treated with curative intent and there had been no clinical signs or symptoms of the malignancy for at least five years.
13. Symptomatic DDD or significant cervical spondylosis at more than two-levels.
14. Spondylolysis.
15. Marked cervical instability on resting lateral or flexion/extension radiographs demonstrated by:
 - Translation \geq 3.5 mm, and/or
 - Greater than 11° angular difference to that of either adjacent level, for both operative levels.
16. Known allergy to cobalt, chromium, molybdenum or polyethylene.
17. Segmental angulation of greater than 11° at treatment or adjacent levels.
18. Reported pregnancy or nursing at time of enrollment, or with plans to become pregnant within the next three years.
19. Reported to have rheumatoid arthritis, lupus, or other autoimmune disease that affect the musculoskeletal system.
20. Congenital bony and/or spinal cord abnormalities that affect spinal stability.
21. Reported to have diseases or conditions that would preclude accurate clinical evaluation (e.g. neuromuscular disorders).
22. Reported concomitant conditions requiring daily, high-dose oral and/or inhaled steroids. High dose steroid use is defined as:
 - Daily, chronic use of oral steroids of 5 mg/day or greater.
 - Daily, chronic use of inhaled corticosteroids (at least twice per day).
 - Use of short-term (less than 10 days) oral steroids at a daily dose greater than 40 mg within one month of the study procedure.
23. Reported to have current or recent history of substance abuse (alcoholism and/or narcotic addiction) requiring intervention.
24. Clinically Severe Obesity, as defined by National Institutes of Health (NIH) Clinical Guidelines Body Mass Index (BMI > 40).
25. Reported use of any other investigational drug or medical device within the last 30 days prior to surgery.
26. Evidence of symptomatic moderate to severe facet joint degeneration or disease where the investigator felt this was a major contributor to the subject's pain as diagnosed by injection and imaging.

27. Reported to be taking medications known to potentially interfere with bone/soft tissue healing (e.g., high-dose oral and/or inhaled steroids, immunosuppressant medication, chemotherapeutic agents).
28. Reported to have pending personal litigation relating to spinal injury (worker's compensation was not an exclusion).
29. Reported to have a current history of heavy smoking (more than one pack of cigarettes per day).
30. Anticipated or potential relocation greater than 50 miles that may interfere with completion of follow-up examinations.
31. Reported to have mental illness or belonged to a vulnerable population, as determined by the investigator (e.g., prisoner or developmentally disabled), that would compromise ability to provide informed consent or compliance with follow-up requirements.
32. Reported to have an uncontrolled seizure disorder.
33. Reported to have taken epidural steroids within 14 days prior to surgery.

COMMONLY REPORTED ADVERSE EVENTS

Commonly Reported AEs Through Month 84	Mobi-C	ACDF
Neck pain	41.0%	61.0%
Arm pain	25.6%	30.5%
Neck and arm pain	5.1%	7.6%
Back pain	36.8%	32.4%
Shoulder pain	29.1%	42.9%
Headache	27.4%	27.6%
Neurological - upper extremity sensory	42.7%	53.3%
Neurological - neck	20.5%	21.0%
Dysphagia	17.1%	22.9%
Dysphonia	2.6%	1.9%
Surgical wound infection	3.4%	3.8%
Nonunion (ACDF only)	–	14.3%
Heterotopic ossification at index levels (Mobi-C only)	8.5%	–
Unanticipated adverse device effect	0.9%	3.8%

NOTE: Adverse event data includes the Mobi-C non-randomized training cases.

APPENDIX (continued)

SUBSEQUENT SURGICAL INTERVENTIONS AT THE INDEX LEVEL – PROCEDURE DETAILS

Treatment Group	Associated AE(s)	Subsequent Surgical Intervention Detail
Mobi-C (n=225)	Hematoma	Revision – repositioned inferior device during hematoma evacuation
	Device migration	Removed inferior device and converted to ACDF
	Ongoing bilateral arm pain	Reoperation - cervical posterior foraminotomy of the inferior index level and the adjacent level below
	Suboptimal bony fixation	Removal of device at both levels and conversion to ACDF
	Neck and shoulder pain	Removal of device at both levels and conversion to ACDF
	Facet spondylosis	Reoperation – posterior bilateral facet decortication at both levels and posterior fusion hardware
	Neck and arm pain	Removal of device at inferior level and conversion to ACDF
	Foraminal stenosis	Revision-Foraminotomy at superior index level
	Cervical spondylosis	Revision of C4-C5 disc arthroplasty (not explanted)
	Trauma (car accident)	Removal of Mobi-C at C4-C5 and replace with Mobi-C
	Neck pain	Removal of Mobi-C and fusion at superior index level
	Cervical spondylosis	Adjacent level discectomy to decompress nerve root
	Osteolysis due to particle disease	Removal of Mobi-C at index levels; C6 corpectomy; C5-C7 partial corpectomy; C5-C7 anterior arthrodesis
	Stenosis	Removal of inferior device at inferior index level and conversion to ACDF; the superior level was left intact

Treatment Group	Associated AE(s)	Subsequent Surgical Intervention Detail
ACDF (n=105)	Pseudarthrosis at both levels	Reoperation – posterior hemilaminotomy at both levels
	Pseudarthrosis at both levels	Supplemental fixation in the form of posterior instrumentation at both levels
	Pseudoarthrosis at superior level	Removal of ACDF hardware and repeat ACDF at the index levels and addition of ACDF at the superior adjacent level
	Pseudarthrosis at the index level	Removal of ACDF hardware and repeat ACDF at the inferior level
	Spondylosis & arthrosis at superior level	Removal of ACDF hardware and repeat ACDF at the superior level
	Pseudoarthrosis at inferior level	Revision – posterior cervical facet fusion at inferior level
	Pseudarthrosis at both levels	Revision – posterior cervical fusion at both levels
	Radiculopathy	Reoperation – hemilaminotomy and posterior decompression at both levels
	Pseudarthrosis at inferior level	Supplemental fixation in the form of posterior fusion instrumentation at the inferior level
	Pseudarthrosis at both levels	Supplemental fixation in the form of posterior fusion instrumentation at both levels and the inferior adjacent level
	Herniated disc at superior adjacent level	Removal of ACDF hardware and extension of fusion with ACDF to superior adjacent level
	Degeneration at adjacent level	Removal of ACDF hardware and adjacent level anterior discectomy and arthroplasty
	Facet syndrome and spondylosis	Removal of ACDF hardware and repeat fusion at inferior index level and extension of fusion at inferior adjacent segment
	Spinal stenosis	Revision – removal of ACDF hardware and extension of fusion to inferior adjacent level
	Herniated disc at inferior and superior adjacent levels	Removal of ACDF hardware, disc replacement at superior adjacent level and fusion at inferior adjacent level
	Motor vehicle accident	Revision – posterior decompression at both index levels
	Cervical spondylosis at adjacent level	Removal of ACDF hardware and fusion at both adjacent levels
	Degeneration at adjacent level	Adjacent level anterior discectomy and interbody fusion

APPENDIX (continued)

INDICATIONS

Visit ZimVie.com for complete clinical study results including indications, contraindications, warnings, precautions, and risks.

The Mobi-C® Cervical Disc Prosthesis is indicated in skeletally mature patients for reconstruction of the disc from C3-C7 following discectomy at two contiguous levels for intractable radiculopathy (arm pain and / or a neurological deficit) with or without neck pain, or myelopathy due to abnormality localized to the level of the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height compared to adjacent levels.

The Mobi-C® Cervical Disc Prosthesis is implanted using an anterior approach. Patients should have failed at least 6 weeks of conservative treatment or demonstrated progressive signs or symptoms despite nonoperative treatment prior to implantation of the Mobi-C® Cervical Disc Prosthesis.

Disclaimer

This document is intended exclusively for physicians and is not intended for laypersons. Information on the products and procedures contained in this document is of a general nature and does not represent and does not constitute medical advice or recommendations.

Because this information does not purport to constitute any diagnostic or therapeutic statement with regard to any individual medical case, each patient must be examined and advised individually, and this document does not replace the need for such examination and/or advice in whole or in part.



Caution

Federal (USA) law restricts this device to sale by or on the order of a physician. Rx Only. Please see the product Instructions for Use for a complete listing of the indications contraindications, precautions, warnings and adverse effects.



Manufactured by

LDR Medical
Parc d'entreprises du Grand Troyes
Quartier Europe de l'Ouest
5, rue de Berlin
10300 Sainte-Savine France
+33 (0)3 25 82 32 63

The clinical data presented is from use of the Mobi-C US implant design which has minor design differences compared to the Mobi-C in other countries.

For more information visit [ZimVie.com](https://www.zimvie.com)

UNITED STATES

10225 Westmoor Drive
Westminster, CO 80021, USA

ASIA-PACIFIC

ZimVie Singapore Pte Ltd,
1 Marina Boulevard, #28-00
One Marina Boulevard,
Singapore 018989

LATIN AMERICA

Av. Pereira Barreto, 1395
19º andar
Torre Sul – Bairro Paraíso
Santo André - São Paulo
CEP: 09190-610, Brazil
+ 55 11 43327755

EUROPE

Parc d'entreprises du Grand Troyes
Quartier Europe de l'Ouest
5 rue de Berlin
10300 Sainte-Savine, France
Adresse postale : CS 80002
10302 Sainte-Savine CEDEX
+33 (0)3 25 82 32 63



Unless otherwise indicated, as referenced herein, all trademarks and intellectual property rights are the property of ZimVie Inc. or an affiliate; and all products are manufactured by one or more of the spinal subsidiaries of ZimVie Inc. (Zimmer Biomet Spine, Inc., Zimmer Spine, LDR Medical, etc.) and marketed and distributed by ZimVie Spine and its authorized marketing partners. For additional product information, please refer to the individual product labeling or instructions for use. Product clearance and availability may be limited to certain countries/regions. This material is intended for clinicians only and does not comprise medical advice or recommendations. Distribution to any other recipient is prohibited. This material may not be copied or reprinted without the express written consent of ZimVie. ZV0025 REV B 07/22 ©2022 ZimVie, Inc. All rights reserved.